
泚å°ã¯åœé²ç·çäž»å°ã®è»äºäœæŠïŒïŒïŒãã®ïŒïŒ
ãæ³åŸã®è§£éäžãðã¯å»è¬åã§ã¯ãªãåœé²ç·çäž»å°ã®è»äºçãªã察çãã§ããã ã®ã詊äœåããèšåºè©Šéšãã€ã³ãã©ãŒã ãã³ã³ã»ã³ããäžèŠã§ã補è¬äŒç€Ÿãæ¥çš®ããå»çåŸäºè
ãäžåå
責ããããâŠ
ãããªãšãã§ããªãå
容ã®ã¬ããŒããæšå¹Žã®æ®ãã«çºè¡šãããŠããŸããã
çºä¿¡è
ã¯ãå
æ²»éšåèšäŒç€Ÿç€Ÿå¡ã§ãä»ã¯ãžã£ãŒããªã¹ãã®Sasha Latypovaããã
è¡æã®å
容ãªã®ã§ãããæ³åŸã絡ã話ãªã®ã§ãªããªãé£è§£ã§ãååŒããã®ã«ãããæéãããã£ãŠããŸããŸããã
ïŒè©³ããæ¹ãããã£ããããŸããããééãããã°ã³ã¡ã³ãæ¬ã§ãæããã ããâŠïŒ
ãããã調ã¹ãã°èª¿ã¹ãã»ã©ããªãæ ¹ãæ·±ããæŽå²ãã ãã¶é¡ãå¿
èŠããããŸããããé°ã§ãšãã§ããªãé·ããªã£ãŠããŸã£ãâŠ
ïŒãªãã¹ãåŒçšç®æãé£ã°ããŠãèªããããã«ããŸããïŒ
è¶
çµ¶é·ãã®ã§ãèšäºãäžåãããã«åå²ããããšã«ããŸããã
ãã®èšäºã§ã¯ãç±³åœä¿å¥çŠç¥çïŒHealth and Human Services; HHSïŒãšç±³åœé£åå»è¬åå±ïŒFood and Drug Administration; FDAïŒãäžå¿ã«ãäŒãããŸãã
âãâãâ
åºç« ãšèšäºã®èŠç¹ïŒå æ²»éšåèšäŒç€Ÿç€Ÿå¡ãæããéåæ
ãã£ããã¯ãðã«ããå¯åå¿ããããçªå·ããšã«ããŸãã«ãã°ãã€ãããã£ãããšãå
ã®è·æ¥æããããç·æ¥æäœ¿çšèš±å¯ãããå»è¬åãšã¯ããããããªããšãããããã®ããšçåã«æã£ãããã§ãã
ïŒæ¯ãè¿ããšããã®éåæããšãŠãæ£ããã£ãããšãåããã®ã§ãããïŒ
ããã§æ
å ±å
¬éè«æ±ã䜿ã£ãŠå
¥æããè³æçãæ³åŸç ç©¶å®¶ã®Katherine Wattãããšäžç·ã«èªã¿ãšããŠãã£ãããã§ãã
ããã§ããã£ãããšã¯âŠâŠ
âç±³åœã®ä»¥äžã®ïŒã€ã®æ³åŸãå¶åºŠãçµã¿åããããšã
ã»ç·æ¥æäœ¿çšèš±å¯ïŒEUAïŒ
ã»å¥çŽé¢ä¿ã®OTA(Other Transactions Authority )
ã»ç¹èš±é¢ä¿ã®PREPæ³
1)ðã¯æµ·å€ããã®è
åšã«å¯Ÿããã察çã
2)ðã¯åœé²ç·çããçºæ³šãããã詊äœåã
ã詊äœåããªã®ã§ãèšåºè©Šéšããå質ä¿èšŒãäžèŠ
3)ðãæ¥çš®ããéã®ã€ã³ãã©ãŒã ãã³ã³ã»ã³ãã¯äžèŠã§ããããªã責任ãããä¿è·ããã
4)ðã補é ãã補è¬äŒæ¥ã«ãæ³çãªè²¬ä»»ããªã
â以äžã®ããšãææ¡ããŠããã®ã¯æ¥µäžéšã
FDAã®å€§å€æ°ã®è·å¡ã§ããçè§£ããŠããªãã£ã
âãããå¯èœã«ããïŒã€ã®æ³å¶åºŠã¯
ç¬¬äºæ¬¡äžç倧æŠåŸããåŸã
ã«å·§åŠã«æ§ç¯ãããŠãã£ã
å®ã«ãšãã§ããªã話ã§ããâŠâŠ
ã§ã¯ãïŒã€ã®æ³å¶åºŠãšãããã«é¢é£ããæ¿åºæ©é¢ãã²ãšã€ã²ãšã€èŠãŠãããŸãããã
第äžç« ïŒç·æ¥æäœ¿çšèš±å¯ïŒEUAïŒãšä¿å¥çŠç¥çãFDA
1ïŒç·æ¥æäœ¿çšèš±å¯ïŒEUAïŒãšã¯
567ãå§ãŸã£ãŠãããEUAãšããèšèããã¥ãŒã¹ã§ããèãããã«ãªããŸããã
å»è¬åã¯ãåºæ¬ãèªå¯å¶ïŒæ¿èªå¶ïŒã§ãã
ââãšããç
æ°ã®æ£è
ããã«ãÃÃãšããçšéã§äœ¿ã£ãŠè¯ãïŒããããé©çšããšåŒãã§ããŸãïŒããšãã颚ã«èš±å¯ïŒæ¿èªïŒãããŸãã
æªæ¿èªã®ãã®ã¯ãã©ããªã«äœ¿ããããŠãæ³ã®æ çµã¿ã®äžã§ã¯äœ¿çšã§ããªãããã§ããããããè²ã
ãªæ¡ä»¶ä»ã§ç·æ¥æã«ç¹å¥ã«èš±å¯ããããšããå¶åºŠãEUAã§ãã
ç±³åœã§ã¯ãé£éŠé£åå»è¬ååç²§åæ³ïŒFederal Food, Drug, and Cosmetic ActïŒFD&C ActïŒã®ç¬¬564æ¡ïŒã»ã¯ã·ã§ã³564ïŒãæ³çæ ¹æ ã«ãªã£ãŠããŸãã
ç±³é£åå»è¬åå±ïŒFDAïŒãç·æ¥æã«æªæ¿èªè¬ãªã©ã®äœ¿çšãèš±å¯ããããæ¢æ¿èªè¬ã®é©å¿ãæ¡å€§ãããããå¶åºŠã®ããšã
FD&C Actã®ç¬¬564æ¡ã«åºã¥ãã
å ·äœçã«ã¯ãFDAãã
ïŒ1ïŒçåœãè ããçŸæ£ã§ããã
ïŒ2ïŒåœè©²è£œåã«é¢ããŠãçŸæ£ã®æ²»çãªã©ã§äžå®ã®æå¹æ§ãèªããããã
ïŒ3ïŒåœè©²è£œåã䜿çšããéã®ã¡ãªãããã補åã®æœåšçãªãªã¹ã¯ãäžåããšå€æã§ããã
ïŒ4ïŒåœè©²è£œå以å€ã«ãçŸæ£ã蚺æãäºé²ããŸãã¯æ²»çããããã®é©åœãªä»£æ¿åãç¡ãââ
ãšããæ¡ä»¶ãæºãããšå€æããå Žåã«çºè¡ã§ããã
2ïŒå§ãŸãã¯AIDS
ç·æ¥æãªãã ãããç¹äŸãèªããã®ã¯åœããåãããã
å
容ãåé¡ç¡ãããã ãâŠâŠ
確ãã«ããèŠãããããããŸããã
ããEUAãšããä»çµã¿ã¯ãã€é ã§ããŠãã©ãããå€é·ã蟿ã£ãŠããã®ãããããèŠãŠã¿ããšãæ¬åœã«ä»ã®å¶åºŠã§è¯ãã®ãïŒãšããçåãåºãŠããã®ã§ãã
EUAã®åã«ããæªæ¿èªè¬ãäŸå€çã«èªããå¶åºŠã¯éå ¬åŒã«ã¯1960幎代ããååšããŠããŸããããæ¬æ Œçã«éå§ãããã®ã¯ãã®AIDSããã§ããïŒãã®æç¹ã§ãã§ã«ããèãâŠïŒã
1980 幎代ã«ããã AIDS/HIV ã®æµè¡ãåããŠïŒé£éŠè¡æ¿èŠåã«ãã FDA ã®èš±å¯ã®ããšã«é倧ãªåã¯æ»ãè¿«ã£ãçŸç ãæã€æ£è ã«å¯ŸããŠæªæ¿èªå»è¬åãæäŸããããã°ã©ã ãå§ãŸã£ãã
ãã ããã®æç¹ã§ã¯ãç¹å¥ãªç æ°ã®æ£è ãããžã®äœ¿çšãæ³å®ããŠãããã€ã³ãã©ãŒã ãã³ã³ã»ã³ããå¿ é ã§ããã
3ïŒæ¹Ÿå²žæŠäºã§è»äººã«æ¡å€§ãICã廿¢
ãããæ¡å€§ãããããšã«ãªã£ãã®ã湟岞æŠäºã§ãåŸè»ããå µå£«ãç¥çµã¬ã¹çã«ããããŠããŸã£ãæã®æ²»çã®ããã«ãæªæ¿èªã®è¬å€ã䜿ããããã«ããã®ã§ãã
ãã®ç«¯ç·ã«ãªã£ãã®ã 1990 幎ã«å§ãŸã£ã湟岞æŠäºã«ãããŠæŽŸé£ãããå µå£«ãå®ãããã®æªæ¿èªå»è¬åã®äœ¿çšã§ããã
åœæïŒãããªãã¹çãæ²»çããããã®ãããªãã¹æ¯çŽ ïŒç¥çµã¬ã¹ã«å¯Ÿããæ²»çè¬ã§ããããªãã¹ãã°ãã³ã¯ããããæ¿èªç³è«ã®ããã®èšåºè©Šéšäžã§ãã£ãïŒãããªãã¹æ¯çŽ ã¯å®å šãªæªæ¿èªïŒããªãã¹ãã°ãã³ã¯å¿ èŠãšãããé©å¿ã«ã€ããŠæªæ¿èªã ã£ãïŒãïŒç±³åœé²è¡çã¯ãã®ããããã®äœ¿çšãå¿ èŠãšå€æã㊠FDA ãšåè°ãïŒFDA ã¯æªæ¿èªã§ãããããã®å»è¬åã®è»éãžã®äœ¿çšãå¯èœãšããããšïŒåã³æªæ¿èªå»è¬åã®äœ¿çšã«åœããæ¬æ¥èŠæ±ããã被éšè ã«å¯Ÿããã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ããå é€ããããšãå 容ãšããæ«å®çèŠåãå¶å®ããã
ãã®éã«ããªããšãã€ã³ãã©ãŒã ãã³ã³ã»ã³ããäžèŠã«ãªã£ãŠããŸããŸããã
4ïŒ911ã§ãã€ãªããçãæ³å®ãäžè¬äººã«æ¡å€§
ããã§ãããŸã ãã®æ®µéã§ã¯å¯Ÿè±¡ã¯ãè»äººãã§ãããäžç¹å®å€æ°ã®äººã
ãæ³å®ããŠããŸããã§ããã
ãããã®åŸã911ãççœèäºä»¶ã®åœ±é¿ã§ãäžè¬äººãžãæ¡å€§ãããããã€ãªã·ãŒã«ãæ³ããšããã®ãåºæ¥ãŠããŸãã®ã§ãã
ããããªããïŒ9.11 åæå€çºããäºä»¶ãšççœèäºä»¶ã¯ïŒè»éãšããäžå®ã®ã°ã«ãŒãã§ã¯ãªãäžè¬åžæ°å šäœã«å¯ŸããŠç·æ¥çãªæªæ¿èªå»è¬åã®äœ¿çšãå¿ èŠãšãªããããšãã匷ãèªèããããããã
2001 幎ç§ã®ççœãã以éïŒççœåã³å€©ç¶çã«å¯Ÿããæ¬¡äžä»£ã¯ã¯ãã³ã®ç¢ºä¿ãé²ããããŠãããïŒååéã®ç¢ºä¿ã®ããã«äŒæ¥ãåããã«ã¯æ§ã ãªæœçãå¿ èŠã§ããããšãèªç¥ãããŠããïŒ
ïŒäžç¥ïŒãããã£ã諞åé¡ã解決ãïŒäŒæ¥ã®åå ¥ãä¿ãã¹ãïŒ2003 幎ã«ãããžã§ã¯ãã»ãã€ãªã·ãŒã«ããäžè¬ææžã§ããã·ã¥å€§çµ±é ã«ããææ¡ããïŒâãã€ãªã·ãŒã«ãæ³ïŒThe Project BioShield Act of2004ïŒâãšããŠïŒ2004 幎 7 æ 21 æ¥ã«æœè¡ãããã
ãã®æ³åŸã¯ïŒããã«å¯Ÿããå»è¬åçã®ç ç©¶éçºä¿é²åã³è£œåã®ç¢ºä¿ãšäœ¿çšãè¿ éåããããã«ä¿å¥çŠç¥çã«ä»¥äžã® 3 ã€ã®æš©éãäžããŠããïŒ
1ïŒãã察çå»è¬åã®èª¿éïŒéçšïŒç ç©¶è³éã®æç¶ãã®ç·©å
2ïŒCBRNïŒChemicalïŒBiologicalïŒRadiologicalïŒNuclearïŒãããªãºã ã«å¯Ÿæããããã®å»è¬åçã®èª¿éã»åžå Žä¿èšŒ
3ïŒFDA ã«èªå¯ãããŠããªãè¬å€çã®ç·æ¥äœ¿çšèš±å¯
ãã€ãªã·ãŒã«ãæ³ã§ã¯ãCBRNãã€ãŸããã€ãªãããæ žã䜿ã£ãè åšã«ãŸã§è©±ãåºããŠããäžè¬äººã«å¯Ÿããè»äºçãªè åšã«ãåããã¹ãã ãããšããããã§ãã
ååŠïŒChemicalïŒãçç©ïŒBiologicalïŒãæŸå°æ§ç©è³ªïŒRadiologicalïŒãæ žïŒNuclearïŒãçšããå µåšã¯ããããã®é æåããšã£ãŠCBRNå µåšãšåŒã°ããããããçšããŠè¡ãããããã¯ãCBRNãããšåŒã°ããŸãã
5ïŒé³¥ã€ã³ãã«ã§ãèªç¶çºçã®è åšãã«ãæ¡å€§
ãããããã®æç¹ã§ãããŸã ãè»äºçãªçç±ã§èµ·ãã£ãè
åšãã«å¯ŸåŠããå Žåã«éå®ãããŠããŸããã
ãããããèªç¶çºççãªè
åšãã«æ¡å€§ãããã®ãã2013幎ã®ããããããã³ãããã¯æ³ãã§ãã
ãã®ãããªç·æ¥äœ¿çšèš±å¯å¶åºŠã¯ïŒäžç¥ïŒåœåïŒåŒ·ã念é ã«çœ®ããŠããã®ã¯è»äºçã«åŒãèµ·ããããå ¬è¡è¡çäžã®ç·æ¥äºæ ã§ãã£ããïŒãã®åŸïŒ2013 å¹Žã®æ³æ¹æ£ã«ãã£ãŠèªç¶ã«çºçããå ¬è¡è¡çäžã®ç·æ¥äºæ ãžã®å¯Ÿå¿ã匷åããæ¹åãžãšå€åããŠããã
ããªãã¡ïŒ2013 å¹Žã«æç«ãããã³ãããã¯åã³å šé åççœå®³æºå忿𩿳ïŒPandemic and All-Hazards Preparedness Reauthorization ActïŒã«ããïŒå ¬è¡è¡çäžã®å±æ©ãå®éã«çºçããåã§ãã£ãŠããã®æããããã°ç·æ¥äœ¿çšèš±å¯ãçºåºããããšãå¯èœãšããïŒææçã®å°èŠæš¡ãªæµè¡ãçºçããæç¹ã§ãã£ãŠããã³ãããã¯ã«åããŠç·æ¥äœ¿çšèš±å¯ãçºåºãïŒå»è¬åã»å»çæ©åšã®éçºãšç·æ¥äœ¿çšèš±å¯ã®çºåºåã³åœè©²å»è¬åã»å»çæ©åšã®åèãè¡ãããšãå¯èœãšãªã£ãã
2013幎ãšããã°âŠïŒ
ãããé³¥ã€ã³ãã«ãšã³ã¶ããæµè¡ã£ãããšãããææã§ãã
ããŒãâŠ
6ïŒæå¹æéãæ€å»
ããããããïŒãã€ããïŒãããã§ããŸã EUAã«ã¯æå¹æéããããŸããã
ãããããã®é³¥ã€ã³ãã«ã®éã«æ€å»ãããŠããŸãã®ã§ãã
ãããŠïŒäºåæºåãå¯èœãšãªã£ãããšã«äœµããŠïŒä¿å¥çŠç¥çé·å®ã«ããç·æ¥äºæ ã®å®£èšã«ã€ããŠå¶åºŠåµèšæã«ä»ãããŠããåå 1 幎ãšããæå¹æéãæ€å»ãããã
èšãæãããšãç·æ¥äºæ ïŒããã¯æ¬¡ã®ç« ã§è©³ãã説æããŸãïŒãç¶ãéãã䜿çšå¯èœãšããããšã«ãªã£ãŠããã®ã§ãã
âãâãâ
ãããã第äžç« ãçµãããŸããïŒæ¢ã«é·ãâŠïŒ
ãããŸã§ããŸãšãããšãEUAã¯AIDSãæ¹Ÿå²žæŠäºã911ãççœèãé³¥ã€ã³ãã«âŠâŠãšã詳ããæ¹ãªããã³ãšããããããããã®ãã€ãã³ããããšã«æ®µéãèžãã§æ³æŽåãé²ã¿ããã³ãããã¯æã«äžè¬äººã«ã䜿çšã§ãããã©ãèªããïŒç¶ïŒã®æä»£ã«ICäžèŠã«ãªã£ãç¶æ
ãæ³å¶åºŠäžã¯ä»ãç¶ããŠããããšããããšã«ãªããŸãããªããšãŸãâŠâŠ
第äºç« ïŒç·æ¥äºæ ã®æå³ãšç·æ¥äºæ 宣èšïŒPHEïŒ
1ïŒèª°ããã€å®£èšããã
ã§ã¯ãEUAã¯ã©ããã£ãŠãçºåãããã®ãïŒ
誰ãããç·æ¥äºæ
ã ãŒïŒããšã宣èšãããå¿
èŠããããŸãã
ããã§ãã誰ãããäœãç·æ¥äºæ
ãšå€æããã®ãããããã調ã¹ãŠèŠãŸããã
ãŸãïŒåæãšããŠã®ç·æ¥äºæ ã®ååšã¯ïŒåœåå®å šä¿éçé·å®ïŒåœé²çé·å®åã¯ä¿å¥çŠç¥çé·å®ã倿ããããšã«ãªããåé·å®ãå€ææš©ãæããç·æ¥äºæ ã¯ããããèŠä»¶ãç°ãªã£ãŠããâŠâŠ
ãããã®ãã¡ã®ããããã®å€æã«åºã¥ããŠä¿å¥çŠç¥çé·å®ã¯ç·æ¥äºæ ã®å®£èšãè¡ãããšãã§ããã
HHSã ãã§ã¯ãªããåœåå®å
šä¿éçãåœé²çãåºãŠæ¥ãŸãããããã§ããEUAãã©ãã©ãæ¡å€§è§£éãããŠããã®ã§ãé¢é£çåºãæ¡å€§ãããŠããããã§ãããã§ãæçµçã«ã¯HHSé·å®ã宣èšããããšã
2020幎ã«ãã€èª°ã宣èšããã®ã確èªããŠã¿ãŸããã
ã玹ä»ããèšäºã®èè
ãLatypovaããã¯ãå¯
ããããšæžããŠããŸããããã¡ãã£ãšéãããã§ãã
ã»ãåœå®¶ç·æ¥äºæ
宣èšãïŒããã¯å¯
ããã宣èšã
ã»ãå
¬è¡è¡çç·æ¥äºæ
宣èšãïŒããã¯ä¿å¥çŠç¥çé·å®ã宣èšã
æ°åã³ãããŠã€ã«ã¹ã«å¯ŸããŠã¯ãåŸè¿°ããããã«3æ13æ¥ã«ãã©ã³ã倧統é ãåœå®¶ç·æ¥äºæ ã宣èšããããå®ã¯1æ31æ¥æç¹ã§ãä¿å¥çŠç¥é·å®ã¢ã¬ãã¯ã¹ã»ã¢ã¶ãŒã®ååã§ãå ¬è¡è¡çç·æ¥äºæ (Public Health Emergency)ã宣èšãããŠãã[5]
ã¡ãªã¿ã«ãWHOãç·æ¥äºæ
宣èšãããŠããŸããããã
ããã¯ãPublic Health Emergency of International Concern, ç¥ç§°: PHEICïŒãšãããã®ã§ãç±³åœã§ã®å®£èšã®åæ¥ã«åºãããŠããŸããã
ãšããããšã¯ãWHOã®å®£èšãåããŠéé«ªå ¥ããã«ç±³åœã§ãHHSé·å®ã宣èšããããããEUAã®æ ¹æ ã«ãªã£ãããšããããšã«ãªããŸãã
2ïŒç·æ¥äºæ 宣èšãšEUAã®é¢ä¿ïŒããããïŒ
ç¹°ãè¿ãã«ãªããŸããã2020幎1æã®ç·æ¥äºæ 宣èšã ãã§ã泚å°ã䜿çšã§ããããã«ãªã£ãããã§ã¯ãããŸããã
2020幎1æ31æ¥ãHHSé·å®ã¯ãâ2019幎æ°åã³ãããŠã€ã«ã¹ïŒ2019-nCoVïŒã®ç¢ºå®çäŸã®çµæãšããŠãå ¬è¡è¡çäžã®ç·æ¥äºæ ãç±³åœã«ååšããããšãæ£åŒã«æ±ºå®ããŸãããâ ããããFDAãææããããã«ããã®å®£èšã«ãã£ãŠFDAã¯EUAãçºè¡ããããšãã§ããŸããã§ãããFDAã®ã¢ã¯ã·ã§ã³ã®ããã«ã¯ãé·å®ã¯FD&Cæ³ç¬¬564æ¡ã®äžã§å¥ã®æ±ºå®ãšå®£èšãããªããã°ãªããŸããã§ããã
ç·æ¥äºæ 宣èšã ãã§ã¯ãªãããã®ããšã«åå¥ã«FDAã®èš±å¯ãå¿ èŠã«ãªããšããããšã®ããã§ãã
ç·æ¥äœ¿çšèš±å¯å¶åºŠã¯ïŒç¬¬äžæ®µéãšããŠã®ç·æ¥äºæ ã®å€æã»å®£èšãåæãšããŠïŒç¬¬äºæ®µéãšããŠã®åå¥ã®å»è¬åã»å»çæ©åšã«å¯Ÿããç·æ¥äœ¿çšèš±å¯ãçºåºãããä»çµã¿ã«ãªã£ãŠããã
ããããå¥ã®èšãæ¹ã§è¡šçŸãããšã
泚å°ãéçºãããŠãããšããŠããç·æ¥äºæ
ãHHSé·å®ã宣èšããFDAãåå¥ã«æ¿èªããŠåããŠãEUAãæ ¹æ ã«æ¥çš®ãå¯èœã«ãªãããšããããã§ãã
âãâãâ
第äžç« ãšç¬¬äºç« ã®ãŸãšã
ä»ã¯HHSé·å®ã宣èšããå
¬è¡è¡çç·æ¥äºæ
宣èšãç¶ããŠãããFDAãã¯ã¯ãã³ã«ã€ããŠEUAãåºããç¶æ
ã
ãšããããšã¯ãä»ã®ðã¯ICãªããŠäžèŠãªã®ã§ãæ¥çš®ããå»çåŸäºè
ããã¡ãããšèª¬æããªãã£ããããªããïŒããšèšŽããããšãã§ããªãããšããããšã«ãªã£ãŠããŸããã§ãã
ããžãâŠâŠ
æ³å¶åºŠã®ã²ãšã€ç®ã ãã§ããªããè
¹ãã£ã±ãã§ãããã
ãããããŸã ãŸã ç¶ããŸãã
次åã¯æ¬äžžïŒïŒïŒã®åœé²ç·çã§ãã
ä¹ããæåŸ
âŠâŠïŒæ°é·ã«åŸ
ã£ãŠããã ãããšå¬ããã§ãâŠâŠïŒ